作者总结了去甲噻肟头孢菌素(Ceftizoxime,简称CZX)在日本和美国临床应用的效果,认为CZX的抗菌谱广,抗菌力强,组织渗透性好,是高度安全有效的第三代头孢菌素,尤其对重症革蓝氏阴性杆菌感染有特效。日本用CZX临床试验各种感染症1,127例,大部分病例的剂量为0.5～2 g,静脉滴注,每天2次,总有效率75.4%,其中内科感染510例,有效率75.9%,泌尿器官感染396例,有效率69.4%,外科与妇产科感染221 The authors summarize the clinical efficacy of ceftizoxime (CZX) in Japan and the United States. CZX is considered as a highly safe and effective third generation cephalosporin Mycotoxins, especially for severe Gram-negative bacilli, have special effects. Japan with CZX clinical trials of various infectious diseases 1,127 cases, the majority of cases a dose of 0.5 ~ 2 g, intravenous infusion, twice daily, the total effective rate was 75.4%, of which 510 cases of medical infection, the effective rate of 75.9%, urinary organs Infection 396 cases, the effective rate of 69.4%, 221 surgical and obstetrics and gynecology